BioReference after the first clean quarter: is the cost reset enough?

The main article on OPKO framed the first quarter as a test for a smaller company that now has to prove it can fund itself. This continuation isolates BioReference because it is one of the most practical tests inside that broader story: did the oncology sale and cost reset create a diagnostics business that can approach breakeven, or only a smaller business that loses less money?

The first quarter is not a fully clean year-over-year comparison, because the prior-year quarter still included the oncology operations sold to Labcorp. That is exactly why the quarter is useful. It splits the revenue decline into two parts: $25.9 million of revenue lost because of the divestiture, and another $4.8 million lost inside the continuing operations because of lower clinical test volumes and lower reimbursement rates.

The prior BioReference analysis marked 2026 as a proof year: 4Kscore and the New York and New Jersey regional core need to replace disposal gains and lost scale. The first quarter gives only a partial answer. Diagnostics operating loss narrowed to $13.0 million from $23.9 million, but gross profit dollars fell to $16.0 million from $18.3 million. The cost reset is working, but the profit base available to cover the remaining expense stack is still too small.

Three points frame the quarter:

• The loss narrowed because expenses fell, not because a new revenue engine emerged. Segment expenses fell by $41.6 million, more than the revenue decline, which improved operating loss by $11.0 million.
• Gross margin rate improved, but gross profit dollars declined. Gross margin rose to about 22.2% from 17.8%, but there were fewer dollars left to cover SG&A, R&D and amortization.
• Continuing operations still eroded. The non-divestiture revenue decline was about $4.8 million, driven by lower test volumes and lower reimbursement rates. That is the signal that cannot be dismissed as a purely technical comparison issue.

The loss is smaller, but the quality still needs proof

In the income statement, BioReference did what it needed to do after selling a large activity: cut costs faster than revenue fell. Diagnostics revenue declined 30% to $72.2 million, while cost of revenue fell 34% to $56.1 million and SG&A fell 31% to $26.2 million. The result was a $13.0 million operating loss, compared with $23.9 million in the prior-year quarter.

That is real progress, but not an endpoint. Gross margin rate rose from about 17.8% to about 22.2%, an improvement of roughly 4.4 percentage points, but gross profit declined by $2.3 million. For an operating business trying to reach breakeven, the dollar amount matters more than the percentage. With only $16.0 million of gross profit against $29.0 million of SG&A, R&D and amortization, the segment is still loss-making.

The chart shows why this quarter is easy to overread. The gross margin rate looks better, but the remaining revenue base is smaller. If continuing operations do not return to growth or at least stabilize, further improvement will come mainly from more cuts rather than from a stronger earnings engine.

Continuing revenue decline is the yellow flag

The most important number in the quarter is the split between revenue lost to the divestiture and revenue lost inside the remaining business. Out of the total $30.7 million decline in diagnostics service revenue, $25.9 million came from the oncology sale. That part was expected. The problem is the rest: another $4.8 million decline in continuing operations, caused by lower testing volume and lower reimbursement rates.

This distinction matters because it separates a cleaner business structure from the quality of the business left behind. A divestiture stops distorting the comparison after a few quarters. Lower test volumes and lower reimbursement rates, by contrast, keep pressuring gross profit every quarter they continue.

The payer mix does not give a simple answer either. Revenue from healthcare insurers fell to $44.6 million from $57.7 million, government payers fell to $9.7 million from $17.2 million, and client payers fell to $15.7 million from $25.3 million. At the same time, the quarter included a $1.0 million positive revenue adjustment from changes in implicit price concession estimates, compared with a $1.5 million negative adjustment in the prior-year quarter. That helps reported revenue, but it also highlights that laboratory revenue is not just test volume times list price. It depends on collection, payer mix and reimbursement estimates that can move after services are provided.

The SG&A cut is the more convincing part

Cost of revenue fell by $28.4 million, but $24.8 million of that decrease was explained by the September 2025 laboratory asset divestiture. The remainder was mainly tied to lower clinical activity costs driven by lower test volumes. In other words, part of the cost-of-revenue improvement is simply a resized activity base, not necessarily better profitability per test.

The SG&A line is higher-quality evidence. Expense fell by $11.8 million, including $6.5 million from divested operations and $5.3 million from cost-reduction initiatives, particularly lease-related expenses. That supports the case that the restructuring was not just a sale of revenue, but also a real reset of the expense base.

Still, SG&A as a share of revenue barely moved: about 36.2% in Q1 2026 versus 36.9% in the prior-year quarter. The dollar amount fell, but revenue fell too. For the cost reset to become a stronger story, expenses need to stay low while continuing revenue stabilizes or grows. Without that, the segment remains in a structure where most additional improvement still depends on more cutting.

The bridge captures the quality issue. BioReference did not generate more gross profit. It spent less below the gross profit line. That is important, but it is not as strong as a business that expands gross profit while holding the cost base down.

4Kscore still matters, but quarterly disclosure remains thin

The constructive BioReference case rests on the national 4Kscore franchise and the clinical and women’s health core in New York and New Jersey. The quarter confirms that this is the business focus left after the sales, but it does not provide a separate 4Kscore KPI: no revenue split, no test count, no growth rate and no gross profit contribution.

Without that detail, it is hard to know whether 4Kscore is already offsetting routine testing pressure or still just a differentiated asset inside a loss-making segment. The market can give the product only limited credit without numbers showing that it is moving segment economics.

The New York and New Jersey core also needs clearer evidence. After the oncology sale, BioReference does not need to return to its former scale. It does need to show that the remaining regional base is dense and profitable enough to support labs, billing infrastructure, sales costs and compliance. The first quarter moves it closer through cost reduction, but not yet through continuing revenue growth.

What would make the next quarter more convincing

The next few quarters have a clear bar. First, the $4.8 million decline in continuing operations needs to stop. If test volumes or reimbursement rates keep falling, the cost improvement will look more like a defensive response to erosion than a transition to a profitable model.

Second, gross profit dollars need to grow again. A 22% gross margin rate is better than last year, but $16.0 million of gross profit is not enough against an expense base of almost $29.0 million. Even a modest increase in gross profit could change the picture if SG&A remains near the current level.

Third, disclosure around 4Kscore needs to improve, or at least the segment needs to show clearer evidence that the urology franchise is pulling revenue upward. Without internal segmentation, BioReference will keep being measured through a broad segment number that makes it hard to separate a growing differentiated product from declining routine testing.

The first quarter leaves a narrow conclusion: the cost reset is already enough to reduce the loss meaningfully, but not enough to prove a breakeven business. If continuing revenue stabilizes and gross profit dollars rise, BioReference can move from a shrinkage story to a profitability recovery story. If not, the market will mostly see a segment that cut expenses well but remains tied to a shrinking revenue base.